A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells
Injection (CD19 CAR-T) Therapy for R/R B-NHL.
Patients will be given a conditioning chemotherapy regimen of fludarabine and
cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Subjects with relapsed and refractory B-cell non-Hodgkin's lymphoma would be selected if
subjects meet all criteria evaluated by physical exams, blood tests, electrocardiograph,
computedtomography （CT）/magnetic resonance Imaging(MRI)/positron emission tomography（PET）,
tumor assessments, etc. Subjects would be hospitalized to receive the infusion of CD19 CAR+ T
cells after lymphodepleting regimen, with the observation and evaluation of efficacy and
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.